Novozymes Expands Collaboration with Upperton

Novozymes Biopharma has expanded its partnership with Nottingham-based research and development company, Upperton Ltd, to offer customers a new albumin conjugation solution. "Novozymes is delighted to unveil Recombumin

Flex along with our new conjugation solution in partnership with Upperton Limited," said Dave Mead, Business Development Director at Novozymes Biopharma. "Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our

experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider."

Richard Johnson, founder and CEO of Upperton Ltd, comments "By combining Novozymes' and Upperton's unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy."